Last reviewed · How we verify

NCT06827483

Adding Neurocognitive Component to Balance Test

ENROLLING BY INVITATION Last updated 5 March 2026
What this trial tests

trial testing Neurocognitive Component in Anterior Cruciate Ligament Injuries in 40 participants. Enrolling by invitation.

Timeline
14 March 2025
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorDuke University
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment40
Start date14 March 2025
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Duke University

Who can join

Adults 18 to 25, any sex, with Anterior Cruciate Ligament Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

By introducing BlazePods as a neurocognitive addition to the YBT, this study aims to determine whether this addition impacts balance performance and/or reach distances between the operative and non-operative limbs of patients recovering from ACL reconstruction. Findings will contribute to optimizing return-to-sport protocols and enhancing late-stage rehabilitation program designs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Anterior Cruciate Ligament Injuries

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06827483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing